Merck Animal Health announced today the FDA approved atinvicitinib tablets (NUMELVI; Merck Animal Health), making it the first and only second-generation Janus kinase (JAK) inhibitor indicated for ...

Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on ...

The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways JAK inhibitors can treat conditions like rheumatoid arthritis, cancer, and some skin and bowel diseases.Some JAK inhibitors have been shown to ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a ...